AbbVie Stock Jumps After Q2 Earnings - Here's Why

AbbVie Inc ABBV has reported Q2 adjusted EPS of $2.91, down 13.6% Y/Y, beating the consensus of $2.80.

Overall sales decreased 4.9% Y/Y (down 4.2% on an operational basis) to $13.87 billion, beating the consensus of $13.52 billion.

The immunology portfolio generated $6.81 billion in sales, down 5.5% (-5% on an operational basis). Humira sales decreased 25.2% to $4.01 billion. 

Related: Growing Competition in Hematology, Aesthetics Complicates AbbVie's Post-Humira Landscape, Analyst Says.

Skyrizi sales reached $1.88 billion (+50.4% Y/Y), and Rinvoq jumped 55.1% to $918 million.

Hematologic oncology portfolio sales were $1.48 billion, down 10.4% (-9.8% on an operational basis). Imbruvica sales decreased 20.8% to $907 million. Venclexta revenues were up 13.1% to $571 million.

Sales from the neuroscience portfolio reached $1.89 billion, +13.6%. Aesthetics portfolio sales increased 1% to $1.38 billion, with $685 million in Botox sales for cosmetic uses.

Guidance: AbbVie has raised FY23 adjusted EPS guidance from $10.57-$10.97 to $10.90-$11.10 versus the consensus of $10.85.

Price Action: ABBV shares are up 5.20% at $149.28 on the last check Thursday.